Table 1.
Clinical characteristics and concentrations of AGEs and OPs at the onset of the clinical trial (n = 168)
| Clinical characteristics | |
| Age (years) | 41.4 ± 10.6 |
| Male | 46 (27) |
| Losartan treatment group | 83 (49) |
| BMI (kg/m2) | 35.7 ± 8.4 |
| Diabetes duration (years) | 8.9 (6.2–14.9) |
| Systolic blood pressure (mmHg) | 118 ± 13 |
| Diastolic blood pressure (mmHg) | 76 ± 8 |
| HbA1c [% (mmol/mol)] | 9.2 ± 2.3 (77.0 ± 25.1) |
| GFR (mL/min) | 164 ± 42 |
| Urinary ACR (mg/g) | 30.6 (13.5–76.3) |
| Biomarker concentrations | |
| Methionine sulfoxide (nmol/L) | 684 (581–803) |
| 2-Aminoadipic acid (nmol/L) | 862 (659–1,098) |
| Carboxymethyl lysine (nmol/L) | 59 (46–74) |
| Glyoxal hydroimidazolone (nmol/L) | 7.3 (6.5–8.6) |
| Carboxyethyl lysine (nmol/L) | 45 (35–58) |
| Methylglyoxal hydroimidazolone (nmol/L) | 71 (47–106) |
| 3-Deoxyglucosone hydroimidazolone (nmol/L) | 194 (160–290) |
Quantitative variables are described by mean ± SD or median (IQR) and qualitative variables by n (%).